... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data



PDX model details

PDX ID 201.2A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
31
Average PDX Generation Time (days +/- SEM) 39 ± 2
Tumor preparation Tumor solid
Tumor Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumor confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 30049486
Markers 201.2A
AR N
PSA N
PSMA N
NE Y
ERG N

Clinical Information

Sample Number 201.2A
Sample Site Lung
Sample source Autopsy
Pathology Tumor Diagnosis Adenocarcinoma
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumor Grade
D'Amico Risk Classification
Tumor Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide

Patient Information

Patient Number 201
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data

Patient Tumor Collection (Current Model)
Tumour sample ID 201.2A
Patient Age (binned in 5 year age groups) 70-74